Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
Date:4/30/2009

onents manufactured by us and sold to other third party medical device manufacturers who assemble those components into finished medical devices. Sales of our Base Medical Products are supported by a small group of direct sales personnel, as well as a network of independent sales representatives and medical product distributors. Sales of our Base Medical Products tend to exhibit greater volatility or slower relative growth, particularly our sales of components to third party medical device manufacturers, which may be impacted by customer concentration and the business issues that certain of our large customers may face, as well as to a more limited extent by economic and credit market conditions. Sales of our Base Medical Products declined by approximately 12% in the first quarter of 2009 as compared to the first quarter of 2008, and declined by approximately 3% as compared to the fourth quarter of 2008. Excluding the impact of foreign currency changes between the respective periods, revenue would have declined by 7% and 3% as compared to the first quarter of 2008 and the fourth quarter of 2008, respectively.

The decline in our Base Medical Products sales as compared to the first quarter of 2008 is due primarily to lower sales of medical device components to other third party medical device manufacturers, particularly sales of surgical needles to one of our largest customers, and to a more limited extent due to negative currency impact relating to sales of certain of our Base Medical Product lines outside of the United States. Manufacturing of surgical needles, as of November 2008, was fully transferred to our facility in Aguadilla, Puerto Rico from our facility in Syracuse, New York. We believe that the closure of our Syracuse production facility in November and the finalization of our move of surgical needle production to Aguadilla, combined with the difficult economic and credit market environment, may have impacted our level of Base Medical Product sales
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Angiotech announces date of annual general meeting of shareholders
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
3. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
4. Angiotech announces positive results from Bio-Seal(TM) clinical study
5. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals announces time change of conference call and webcast
8. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
9. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
10. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... , Sept. 15, 2014  FlexTech Alliance ... for flexible, printed product demonstrators (demos) and a ... RFP process with pre-proposals due on October 22, ... Funds for proposals ultimately selected are provided by ... a significant cost share by the proposing organization. ...
(Date:9/15/2014)... fast when a patient has sepsis, a life-threatening condition ... blood -- often too fast for antibiotics to help. ... developed by a team at Harvard,s Wyss Institute for ... treat sepsis. , "Even with the best current ... at least 30 percent of the time," said Mike ...
(Date:9/15/2014)... interdisciplinary team of researchers led by Northeastern University ... precise inter-nanotube junctions and a variety of nanocarbon ... facile and easily scalable, which will allow the ... networks for use in applications ranging from electronic ... from cars to sports equipment. , Their findings ...
Breaking Biology Technology:Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... International,Corporation (Nasdaq: PRXL ), a leading ... as a Vice President and General,Manager in ... brings more than 20 years of experience ... position, Ms. Fisher leads a global,team of ...
... Healing ... of Chronic Wounds, ... company focused on improving patient quality of life, today,announced that ... its KFH Novo medical device, a breakthrough medical,technology that enhances ...
... a.m. ET; 8:00 a.m. PT, VANCOUVER and SAN ... MGIFF), a clinical-stage developer of drugs for infectious,diseases, will ... 13,2008 at 11:00 a.m. ET (8:00 a.m. PT) to ... 31, 2008 and provide an update on,company activities. To ...
Cached Biology Technology:PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team 2PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team 3PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team 4Kingfisher Healthcare Receives European CE Mark for Next Generation Wound Healing Device 2
(Date:9/15/2014)... outbreak in West Africa, which has claimed more than ... understanding of the molecular biology of the virus that ... antiviral drugs to treat or prevent Ebola hemorrhagic fever. ... USA under the leadership of Dr Dan Engel, ... has obtained the crystal structure of a key ...
(Date:9/15/2014)... it,s not what comes to mind when you think ... Doncaster,s 310-million-year-old past, including a fossilised shark egg case, has ... the fossilised plants and creatures may even be new to ... crabs and some previously unrecorded seed pods are amongst the ... within the coal and shale deposits in what is one ...
(Date:9/15/2014)... reports about the need for vitamin E and how ... that adequate levels of this essential micronutrient are especially ... who are or may become pregnant. , A lifelong ... said, but often complicated by the fact that this ... through diet alone. It has been estimated that only ...
Breaking Biology News(10 mins):Protein secrets of Ebola virus 2'Jaws' lived in Doncaster 2Vitamin E intake critical during 'the first 1,000 days' 2Vitamin E intake critical during 'the first 1,000 days' 3
... shrimp. Fried eggs. Burgers and fries. New research suggests ... foods are so appealing together. It has been known ... uptake, but fundamental aspects of that process remain poorly understood. ... for Science are using zebrafish to better understand the cellular ...
... People with celiac disease struggle with limited food choices, ... in wheat and other grains. Researchers from the University ... banana flour, which tasters found more acceptable than regular whole ... cheaper to produce than standard pastas. Their research is ...
... first paternity study of southern right whales has found a ... say, which is good news for the overall genetic diversity ... through in-breeding. Results of the study, by researchers at ... Zealand Department of Conservation, have just been published in the ...
Cached Biology News:Zebrafish research shows how dietary fat regulates cholesterol absorption 2Pasta made from green banana flour a tasty alternative for gluten-free diets 2First paternity study of southern right whales finds local fathers most successful 2First paternity study of southern right whales finds local fathers most successful 3
...
Request Info...
... vectors carry the kanamycin resistance gene that ... Spontaneous generation of multiple insertion events can ... of Geneticin Reagent. Pichia transformants are selected ... level of resistance to Geneticin Reagent. The ...
... Synthetic peptide derived from the C-terminal ... Math-2. Specificity: Specific for the ... (positive controls: human U251 A172 IMR-32 ... rat brain homogenates)Storage: Store at -20C ...
Biology Products: